Treatment of Carbapenem-Resistant Enterobacterales: guidelines from IDSA. ( Pranita D. Tamma and al. )

Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections A Focus on Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

| Dr Jean-Pierre Bru

The IDSA publishes guidelines for the treatment of infections due to Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas … Suite  

Does Colistin-Meropenem combination therapy reduce the emergence of colistin resistance vs. Colistin monotherapy? ( Dickstein Y. et al. & AIDA study group. )

Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.

| Dr Jean-Pierre Bru

Colistin is one of a limited number of options for the treatment of carbapenem-resistant Gram-negative bacteria. A previously published randomized … Suite